Dianthus Therapeutics (DNTH) Total Current Liabilities (2017 - 2025)

Dianthus Therapeutics' Total Current Liabilities history runs 9 years deep, the most recent figure standing at $30.7 million for Q4 2025.

• In Q4 2025, Total Current Liabilities rose 66.55% year-over-year to $30.7 million; the TTM figure through Dec 2025 stood at $30.7 million (up 66.55% YoY), while the FY2025 annual figure was $30.7 million, up 66.55% from the prior year.
• Total Current Liabilities was $30.7 million for Q4 2025 at Dianthus Therapeutics, up from $23.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $30.7 million in Q4 2025 to a low of $4.0 million in Q2 2023.
• Historically, Total Current Liabilities has averaged $13.3 million across 5 years, with a median of $11.2 million in 2021.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities sank 64.16% in 2023, then soared 148.61% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $10.9 million in 2021, then declined by 24.28% to $8.2 million in 2022, then gained by 17.09% to $9.6 million in 2023, then soared by 91.59% to $18.5 million in 2024, then surged by 66.55% to $30.7 million in 2025.
• The last three Total Current Liabilities figures came in at $30.7 million (Q4 2025), $23.9 million (Q3 2025), and $20.1 million (Q2 2025), per Business Quant data.